|Bid||76.96 x 800|
|Ask||80.00 x 1100|
|Day's Range||75.32 - 77.67|
|52 Week Range||34.92 - 79.95|
|Beta (5Y Monthly)||1.70|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2020 - Mar 2, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||100.19|
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on December 1, 2019, the compensation committee of GBT’s.
Global Blood Therapeutics broke out to new highs last week and remains strong today. Let's check out the charts of this clinical-stage biopharmaceutical company. In this daily bar chart of GBT, below, we can see that prices made a straight up rally in November breaking above the June 2019 highs.
The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.
The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 26) Allakos Inc (NASDAQ: ALLK ) Alnylam Pharmaceuticals, ...
Global Blood's (GBT) Oxbryta wins the FDA nod to address sickle cell disease in patients aged 12 years and above. The approval comes three months ahead of schedule.
GBT stock briefly broke out Tuesday after Global Blood Therapeutics gained earlier-than-expected approval of a sickle cell treatment. The drug, called Oxbryta, is a once-daily tablet.
Shares of Global Blood Therapeutics jumped 11% in premarket trading following the announcement Monday evening that the Food and Drug Administration had approved Oxbryta, its sickle cell disease treatment. It's the second sickle cell drug approved by the FDA this month. Novartis's Adakveo was approved by the regular on Nov. 15. The monthly wholesale acquisition cost for Adakveo is between $7,071 and $9,428; for Oxbryta, it's $10,417 per month. SunTrust Robinson Humphrey analysts forecast $69 million in sales of Oxbryta in 2020 and raised their price target to $110 from $100. Global Blood Therapeutics' stock has rallied 46% year-to-date, while the S&P 500 is up 25%.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam ...
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the following investor conferences in.
Global Blood Therapeutics gained Food and Drug Administration approval for a new sickle cell treatment on Monday, three months ahead of expectations. GBT stock surged ahead of the news.
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (GBT) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Oxbryta™ (voxelotor) tablets for the treatment of sickle cell disease (SCD) in adults and children 12 years of age and older.1 Oxbryta, an oral therapy taken once daily, is the first approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD.2,3 The medicine is expected to be available through GBT’s specialty pharmacy partner network within two weeks.
The U.S. Food and Drug Administration said on Monday it approved a drug from Global Blood Therapeutics Inc to treat sickle cell disease in adults and children 12 years or older. It is the second drug in recent days to win U.S. approval for sickle cell anemia, and the first to target the underlying cause of the disease rather than symptoms. Last week Novartis AG's Adakveo won U.S. regulatory clearance to reduce the incidence of sickle cell-related pain crises, a common and debilitating symptom of the disease.
Serving on the board of a South San Francisco company on the cusp of a drug approval may have helped this Democratic Party candidate for president gain insight into drug pricing. It also may make him a target for other candidates.
Global Blood (GBT) incurs a wider-than-expected loss in the third quarter of 2019. Moreover, voxelotor for the treatment of sickle cell disease is under review in the United States.
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the third.